Advanced/metastatic bladder cancer: current status and future directions

被引：37

作者：

Facchini, G. ^{[1
]}

Cavaliere, C. ^{[2
]}

Romis, L. ^{[3
]}

Mordente, S. ^{[3
]}

Facchini, S. ^{[4
]}

Iovane, G. ^{[5
]}

Capasso, M. ^{[5
]}

D'Errico, D. ^{[5
]}

Liguori, C. ^{[1
]}

Formato, R. ^{[1
]}

Cicala, S. ^{[1
]}

Andreozzi, F. ^{[6
]}

Di Lauro, G. ^{[3
]}

Imbimbo, C. ^{[4
]}

Vanni, M. ^{[7
]}

D'Aniello, C. ^{[8
]}

机构：

[1] ASL NA 2 Nord SM delle Grazie Hosp, UOC Med Oncol, Pozzuoli, NA, Italy

[2] ASL NA 3 Sud Osped Riuniti Area Nolana, UOC Med Oncol, Nola, NA, Italy

[3] ASL NA 2 Nord SM delle Grazie Hosp, UOC Urol, Pozzuoli, NA, Italy

[4] Univ Federico II Napoli, Dept Urol, Naples, Italy

[5] IRCCS Fdn G Pascale, Dept Unit Clin & Expt UroAndrol Oncol, Ist Nazl Tumori, Naples, Italy

[6] Univ Naples 2, Med Oncol, Naples, Italy

[7] Hlth Manager ASL NA 2 Nord, Naples, Italy

[8] AORN COLLI Osped Monaldi Cotugno CTO, Div Med Oncol, Naples, Italy

来源：

EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES | 2020年 / 24卷 / 22期

关键词：

Bladder cancer; Chemotherapy; Prognostic factors; Immunotherapy; METASTATIC UROTHELIAL CARCINOMA; TRANSITIONAL-CELL-CARCINOMA; ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; OPEN-LABEL; FACTOR RECEPTOR; DOUBLE-BLIND; COMPARING GEMCITABINE; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT;

D O I：

10.26355/eurrev_202011_23795

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In 2015 bladder cancer was the fourth most frequent malignancy and the eighth cause of death for cancer. At diagnosis, about 30% of bladder cancer (BC) patients present a muscle-invasive bladder cancer (MIBC) and 5% a metastatic bladder carcinoma (MBC). For fit MBC patients, combination chemotherapy (CC) is the standard of care for first-line treatment. CC includes both the treatment with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) either the classical or the dose-dense MVAC regimen, and the doublet therapy with cisplatin and gemcitabine (CG). Median progression free survival (PFS) was 7 months and median overall survival (OS) was 15 months. The present review provides an update on the management of MBC, with focus on target therapies, immune checkpoint inhibition, looking for prognostic and predictive factors.

引用

页码：11536 / 11552

页数：17

共 50 条

[31] Cancer vaccines: current status and future directions
Zhou, Yingqiong
Wei, Yuquan
Tian, Xiaohe
Wei, Xiawei
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2025, 18 (01)
[32] Botulinum toxin a in the overactive bladder: Current status and future directions
Mallina, Ravi
Sahai, Arun
Khan, Mohammed S.
Dasgupta, Prokar
BJU INTERNATIONAL, 2007, 99 (06) : 1549 - 1550
[33] Botulinum toxin A in the overactive bladder: current status and future directions
Dmochowski, Roger
Sand, Peter K.
BJU INTERNATIONAL, 2007, 99 (02) : 247 - 262
[34] Bladder cancer biomarkers: current approaches and future directions
Ahangar, Melika
Mahjoubi, Frouzandeh
Mowla, Seyed Javad
FRONTIERS IN ONCOLOGY, 2024, 14
[35] Metastatic Colorectal Cancer: Current State and Future Directions
Fakih, Marwan G.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (16) : 1809 - +
[36] Can We Conquer Advanced Head and Neck Cancer? Current Status and Future Directions
Won, Ho-Ryun
Koo, Bon Seok
CLINICAL AND EXPERIMENTAL OTORHINOLARYNGOLOGY, 2021, 14 (02) : 145 - 146
[37] Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise
Zachos, Ioannis
Konstantinopoulos, Panagiotis A.
Tzortzis, Vassilios
Gravas, Stavros
Karatzas, Anastasios
Karamouzis, Michalis V.
Melekos, Michael
Papavassiliou, Athanasios G.
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (07) : 875 - 887
[38] Advanced Acral Melanoma Therapies: Current Status and Future Directions
Yiqun Zhang
Shijie Lan
Di Wu
Current Treatment Options in Oncology, 2022, 23 : 1405 - 1427
[39] Advanced Acral Melanoma Therapies: Current Status and Future Directions
Zhang, Yiqun
Lan, Shijie
Wu, Di
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (10) : 1405 - 1427
[40] Non-metastatic castration-resistant prostate cancer: current status and future directions
Gupta, Ruby
Sheng, Iris Y.
Barata, Pedro C.
Garcia, Jorge A.
EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (06) : 513 - 522

← 1 2 3 4 5 →